Evidence map›Paper›PMID 38124494›Full record

ArticleAmerican journal of hypertension2024

Medical Measures in Hypertensives Considered Resistant.

Fadl Elmula M Fadl Elmula, Julian Eek Mariampillai, Sondre Heimark, Sverre E Kjeldsen, Michel Burnier

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in American journal of hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Fadl Elmula M Fadl ElmulaDivision of Medicine, Ullevaal University Hospital, Cardiorenal Research Centre, Oslo, Norway.ORCID 0000-0003-0421-8528
Julian Eek MariampillaiDepartment of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.ORCID 0000-0002-3857-9797
Sondre HeimarkDivision of Medicine, Ullevaal University Hospital, Cardiorenal Research Centre, Oslo, Norway.ORCID 0000-0001-8050-7765
Sverre E KjeldsenDivision of Medicine, Ullevaal University Hospital, Cardiorenal Research Centre, Oslo, Norway.ORCID 0000-0003-2389-0272
Michel BurnierFaculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1283-8487
Oslo University Hospital · NOLovisenberg Diakonale Høgskole · NOUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with resistant hypertension are the group of hypertensive patients with the highest cardiovascular risk.

methodsAll rules and guidelines for treatment of hypertension should be followed strictly to obtain blood pressure (BP) control in resistant hypertension. The mainstay of treatment of hypertension, also for resistant hypertension, is pharmacological treatment, which should be tailored to each patient's specific phenotype. Therefore, it is pivotal to assess nonadherence to pharmacological treatment as this remains the most challenging problem to investigate and manage in the setting of resistant hypertension.

resultsOnce adherence has been confirmed, patients must be thoroughly worked-up for secondary causes of hypertension. Until such possible specific causes have been clarified, the diagnosis is apparent treatment-resistant hypertension (TRH). Surprisingly few patients remain with true TRH when the various secondary causes and adherence problems have been detected and resolved. Refractory hypertension is a term used to characterize the treatment resistance in hypertensive patients using ≥5 antihypertensive drugs. All pressor mechanisms may then need blockage before their BPs are reasonably controlled.

conclusionsPatients with resistant hypertension need careful and sustained follow-up and review of their medications and dosages at each term since medication adherence is a very dynamic process.

Indexed as

Antihypertensive AgentsHypertensionBlood PressureHumansMedication AdherenceVasoconstrictor AgentsAntihypertensive AgentsVasoconstrictor Agentsadherenceantihypertensive drugsblood pressurehypertensionrefractory hypertensiontreatment resistance

Identifiers

PMID38124494
PMCPMC11016838
OpenAlexW4390062629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.